Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Taenia solium neurocysticercosis (NCC) is a parasitic infection causing much neurological
disease in most of the world. When parasites locate in the cavities around the brain
(subarachnoid NCC, SANCC), it becomes an aggressive, progressive and frequently lethal
presentation. Current treatment regimens for SANCC have quite limited efficacy. The
investigators propose to compare the current standard of care (a single antiparasitic drug,
albendazole) with a combined regimen using two antiparasitic drugs simultaneously by adding
praziquantel. The trial will enrol 164 patients in four centers, two in Peru, one in Ecuador,
and one in Brasil.